Literature DB >> 11200151

Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer.

E P Mitchell1.   

Abstract

Irinotecan (CPT-11, Camptosar) is a semisynthetic water-soluble derivative of the plant alkaloid camptothecin. This review will focus on the potential use of irinotecan in combination with fluorouracil (5-FU) in the preoperative combined-modality treatment of advanced rectal cancer. The laboratory studies that define the mechanism of fluoropyrimidine- and camptothecin-mediated radiosensitization are discussed, and the rationale for combined-modality therapy using radiation with 5-FU and irinotecan is presented.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11200151

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  5 in total

1.  Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.

Authors:  Mohammed Mohiuddin; Rebecca Paulus; Edith Mitchell; Nader Hanna; Albert Yuen; Romaine Nichols; Salochna Yalavarthi; Cherie Hayostek; Christopher Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-29       Impact factor: 7.038

Review 2.  Toward the non-surgical management of locally advanced rectal cancer.

Authors:  Alice Dewdney; David Cunningham
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

3.  Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer.

Authors:  Masayoshi Yasui; Masataka Ikeda; Mitsugu Sekimoto; Hirofumi Yamamoto; Ichiro Takemasa; Takafumi Ueda; Junzo Shimizu; Mutsumi Fukunaga; Osamu Suzuki; Takehiro Inoue; Morito Monden
Journal:  World J Surg Oncol       Date:  2006-11-22       Impact factor: 2.754

4.  A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.

Authors:  F Willeke; K Horisberger; U Kraus-Tiefenbacher; F Wenz; A Leitner; A Hochhaus; R Grobholz; A Willer; G Kähler; S Post; R-D Hofheinz
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

5.  Good response to neoadjuvant chemoradiotherapy predicts good oncological outcome in locally advanced rectal cancer.

Authors:  Chi Zhang; Liping Xu; Qin Qin; Jia Liu; Xinyu Tang; Nan Jiang; Zhaoyue Zhang; Fei Li; Hongyan Cheng; Jiayan Chen; Xinchen Sun
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.